290 related articles for article (PubMed ID: 15097243)
1. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Tanabe A; Naruse M; Hara Y; Sato A; Tsuchiya K; Nishikawa T; Imaki T; Takano K
J Hypertens; 2004 May; 22(5):1017-23. PubMed ID: 15097243
[TBL] [Abstract][Full Text] [Related]
2. Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
Naruse M; Tanabe A; Hara Y; Takagi S; Imaki T; Takano K
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S1-3. PubMed ID: 15838251
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
Naruse M; Tanabe A; Sato A; Takagi S; Tsuchiya K; Imaki T; Takano K
Hypertension; 2002 Jul; 40(1):28-33. PubMed ID: 12105134
[TBL] [Abstract][Full Text] [Related]
4. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
5. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Taniguchi I; Kawai M; Date T; Yoshida S; Seki S; Taniguchi M; Shimizu M; Mochizuki S
Circ J; 2006 Aug; 70(8):995-1000. PubMed ID: 16864931
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Ikeda Y; Nakamura T; Takano H; Kimura H; Obata JE; Takeda S; Hata A; Shido K; Mochizuki S; Yoshida Y
J Lab Clin Med; 2000 Apr; 135(4):353-9. PubMed ID: 10779052
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Kim S; Zhan Y; Izumi Y; Iwao H
Hypertension; 2000 Mar; 35(3):769-74. PubMed ID: 10720593
[TBL] [Abstract][Full Text] [Related]
8. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
Brilla CG; Weber KT
Cardiovasc Res; 1992 Jul; 26(7):671-7. PubMed ID: 1423431
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
Nicoletti A; Heudes D; Hinglais N; Appay MD; Philippe M; Sassy-Prigent C; Bariety J; Michel JB
Hypertension; 1995 Jul; 26(1):101-11. PubMed ID: 7607712
[TBL] [Abstract][Full Text] [Related]
10. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection.
Peng F; Lin J; Lin L; Tang H
Int J Mol Med; 2012 Dec; 30(6):1376-86. PubMed ID: 23064712
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats.
Okada T; Nagai M; Taniguchi I; Kuno M; Imamoto S; Seki S; Taniguchi M; Mochizuki S
Int Heart J; 2006 Sep; 47(5):783-93. PubMed ID: 17106149
[TBL] [Abstract][Full Text] [Related]
12. Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction.
Matsumoto R; Yoshiyama M; Omura T; Kim S; Nakamura Y; Izumi Y; Akioka K; Iwao H; Takeuchi K; Yoshikawa J
Circ J; 2004 Apr; 68(4):376-82. PubMed ID: 15056838
[TBL] [Abstract][Full Text] [Related]
13. Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
Liang YH; Wang JM; Zhou Y; Jiang XJ; Jiang H; Huang CX
Life Sci; 2004 Aug; 75(15):1871-8. PubMed ID: 15302230
[TBL] [Abstract][Full Text] [Related]
14. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage.
Baumann M; Hermans JJ; Janssen BJ; Peutz-Kootstra C; Witzke O; Heemann U; Smits JF; Boudier HA
J Hypertens; 2007 Dec; 25(12):2504-11. PubMed ID: 17984673
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L; Duce B; Miric G; Sernia C
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
17. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
Okazaki H; Minamino T; Tsukamoto O; Kim J; Okada K; Myoishi M; Wakeno M; Takashima S; Mochizuki N; Kitakaze M
Hypertens Res; 2006 Apr; 29(4):277-84. PubMed ID: 16778335
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Hirono Y; Yoshimoto T; Suzuki N; Sugiyama T; Sakurada M; Takai S; Kobayashi N; Shichiri M; Hirata Y
Endocrinology; 2007 Apr; 148(4):1688-96. PubMed ID: 17218415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
